|
John P. Longenecker, Ph.D. has more than 22 years experience in the biotech/pharmaceutical arena prior to joining Favrille, Inc. in February 2002. His experience includes the growth of two biotechnology companies from start up to product approval. He has participated in all aspects of company development including public offerings, venture capital funding, corporate partnering and management of collaborations, mergers and acquisitions. In 1992, Dr. Longenecker joined DepoTech as Senior Vice President of Research, Development and Operations and then served as President and COO from February 1998 to March 1999. Under Dr. Longenecker's leadership, DepoTech took its lead product, Depocyt, from early pre-clinical research and development through to commercial launch. Depocyt is approved for the treatment of lymphomatous meningitis, a condition that occurs when a lymphoma spreads to the brain and spinal column. Following SkyePharma PLCs acquisition of DepoTech in 1999, Dr. Longenecker served as President for the U.S. operations of SkyePharma Inc. and as a Member of the Executive Committee for SkyePharma PLC. From 1982 to 1992, Dr. Longenecker was at Scios (Cal Bio), a biotechnology company in the San Francisco Bay Area. He was Vice-President and Director of Development at Scios from 1986 to 1992. Dr. Longenecker was also a Director of a number of Cal Bio subsidiaries during this period including Meta Bio and Karo Bio. Dr. Longenecker holds a B.S. in Chemistry from Purdue University in Lafayette, Indiana and a Ph.D. in Biochemistry from The Australian National University in Canberra, Australia. He was a post doctoral fellow at Stanford University from 1980 to 1982. | 